Page 6 - Flipbook
P. 6
Abstracts – Oral session
4503 M. Galsky et al. Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in
patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257
4504 A. Balar et al. Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent
hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive
urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial
4505 X. del Muro et al. Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in
patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective
bladder preservation approach: IMMUNOPRESERVE-SOGUG trial
Combination of RT with immune-checkpoint inhibitors
Radiation Oncology
